Dynavax Technologies Corp

NASDAQ:DVAXUnited States

Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company, which is engaged in developing and commercializing vaccines. The Company's products include HEPLISAV-B hepatitis B vaccine and CpG 1018. Its HEPLISAV-B ((Recombinant)(Adjuvanted) is indicated for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. It also manufactures and sells CpG 1018 adjuvant, the adjuvant used in HEPLISAV-B. It is also engaged in developing a multi-program clinical pipeline leveraging CpG 1018 adjuvant to develop improved vaccines for indications with unmet medical needs. Its Pipeline programs include vaccine candidates under development for shingles, tetanus, diphtheria, and pertussis (Tdap) and plague. Its Shingles vaccine program Z-1018, which is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.

Contact Information

Headquarters

2100 Powell Street, Suite 720EMERYVILLE, CA, United States 94608

Phone

510-848-5100

Fax

510-848-1327

Executives

Independent Chairman of the Board

Scott Myers

Interim Co-President, Co-Principal Executive Officer

David Novack

Chief Executive Officer, Interim Chief Financial Officer, Director

Ryan Spencer

Senior Vice President, General Counsel

John Slebir

Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs

Robert Janssen